[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Buddhist Tzu Chi General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":329},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,40,63,83,101,134,160,188,212,230,255,281,303],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100652964","children-receiving-monocular-misight-1-day-treatment-for-unilateral-myopia-100652964",false,"NCT07778264","Children Receiving Monocular MiSight® 1 Day Treatment for Unilateral Myopia","Natural History and Post-Conversion Clinical Outcomes of the Fellow Eye in Children Receiving Monocular MiSight® 1 Day Treatment for Unilateral Myopia: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age 7-18 years.\n2. Cycloplegic SER ≤ -0.75 D in one eye and \\> -0.50 D in the fellow eye.\n3. Cylinder ≤1.00 D in the myopic eye.\n4. BCVA ≥20\u002F25 (0.1 logMAR).\n5. Willingness to wear MiSight® 1 Day for ≥10 hours\u002Fday and ≥6 days\u002Fweek.\n6. Willingness of the participant and parents to comply with the study procedures and complete 12 months of follow-up.\n7. Written informed consent provided by the legal guardian.\n\nExclusion Criteria:\n\n* Previous orthokeratology treatment.\n* Previous atropine treatment exceeding one month.\n* Previous use of other myopia-control soft contact lenses.\n* Keratoconus, corneal degeneration, or other corneal disease.\n* Amblyopia, strabismus, or other significant binocular visual dysfunction.\n* Cataract, glaucoma, uveitis, retinal disease, or other significant ocular disease.\n* Systemic connective-tissue or neurological disease affecting vision.\n* Known allergy to atropine or contact lens materials.\n* Inability to comply with scheduled visits or anticipated relocation during the study period.","ALL","7 Years","18 Years",{"count":20,"type":21},100,"ESTIMATED","100 Months","OBSERVATIONAL","This investigator-initiated prospective observational cohort study aims to establish the first longitudinal clinical database evaluating fellow-eye myopia development in children receiving monocular MiSight® 1 Day treatment for unilateral myopia.\n\nAll myopic eyes will receive MiSight® 1 Day as standard clinical care, while the fellow eye will undergo regular observation without prophylactic intervention. If the fellow eye develops myopia (cycloplegic spherical equivalent ≤ -0.50 D), standard myopia control treatment, including MiSight® 1 Day or 0.05% atropine ophthalmic solution, will be initiated according to routine clinical practice and shared decision-making between the investigator and the child's parents The findings are expected to provide important evidence regarding fellow-eye refractive development, identify predictors of myopia conversion, optimize the timing of intervention, and support personalized myopia management in children with unilateral myopia.",[26,27],"Myopia (Disorder)","Anisometropia","NOT_YET_RECRUITING","2026-08-18",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":21},"2026-09-15",{"date":36,"type":21},"2029-12-31",{"name":38,"class":39},"Buddhist Tzu Chi General Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100649293","multilevel-multimodal-neurophysiological-integration-for-investigating-the-network-modulatory-mechanisms-of-epidural-spinal-cord-stimulation-100649293","NCT07732972","Multilevel Multimodal Neurophysiological Integration for Investigating the Network Modulatory Mechanisms of Epidural Spinal Cord Stimulation","Inclusion Criteria:\n\nA. Non-Spinal Cord Injury (Non-SCI) Group\n\n* Individuals without spinal cord injury.\n* Patients diagnosed with chronic neuropathic pain who meet the criteria for routine temporary epidural spinal cord stimulation (EES) implantation therapy.\n* Patients who have undergone temporary epidural spinal cord stimulation (EES) implantation.\n* Ability to understand and follow motor instructions.\n* Age between 20 and 70 years. B. Spinal Cord Injury (SCI) Group\n* Patients with chronic spinal cord injury.\n* Patients who have undergone temporary epidural spinal cord stimulation (EES) implantation.\n* American Spinal Injury Association Impairment Scale (AIS) grades A-D.\n* Spinal cord injury levels between C3 and L1.\n* Ability to understand and follow motor instructions.\n* Age between 20 and 70 years.\n\nExclusion Criteria:\n\n* Individuals with severe psychiatric disorders or cognitive impairments, including major depressive disorder, schizophrenia, or dementia, that may affect their ability to understand the study procedures or comply with study instructions.\n* Individuals who are unable to maintain consciousness, follow instructions, or complete study tasks, including motor tasks, isometric contractions, or resting-state tasks.\n* Individuals with severe medical conditions and unstable clinical status, such as uncontrolled cardiovascular disease, severe infection, respiratory failure, or other conditions deemed unsuitable for study participation by the attending physician.\n* Individuals with abnormal positioning, inadequate fixation, or complications related to temporary epidural spinal cord stimulation (EES) leads, including infection, significant pain, or neurological deterioration, as determined by clinical evaluation to be unsuitable for study recordings.\n* Individuals currently using medications that may significantly affect neurophysiological signals, such as high-dose sedatives, anesthetic agents, or other medications considered by the research team to interfere with data interpretation.","20 Years","70 Years",{"count":49,"type":21},30,"This study will examine how the brain, spinal cord, and muscles communicate in people with spinal cord injury. Researchers will use noninvasive brain and muscle recordings together with spinal electrical recordings to better understand how epidural spinal cord stimulation (EES) affects nerve function. The results may help develop more effective and personalized rehabilitation treatments for people with spinal cord injury.",[52],"Spinal Cord Injury(SCI)","RECRUITING","2026-07-23",{"date":56,"type":32},"2026-07-29",{"date":58,"type":21},"2026-08-01",{"date":60,"type":21},"2030-12-31",{"name":38,"class":39},1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":47,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":62},"100648576","exploration-of-the-effectiveness-and-mechanism-of-personalized-epidural-electrical-stimulation-in-improving-upper-limb-function-in-participants-with-spinal-cord-injury-100648576","NCT07722429","Exploration of the Effectiveness and Mechanism of Personalized Epidural Electrical Stimulation in Improving Upper Limb Function in Participants With Spinal Cord Injury","Inclusion Criteria:\n\n* Age between 18 and 70 years.\n* Duration since spinal cord injury ranging from 1 to 10 years.\n* Spinal cord injury level at or above T4.\n* MRI and\u002For CT imaging confirms adequate spinal cord decompression and spinal stability.\n* Stable vital signs and no dependence on mechanical ventilation.\n* Stable neurological and psychological status, with no history of neurological deterioration within the past 6 months (e.g., acute worsening of motor or sensory function, new-onset seizures, acute changes in muscle tone, or other neurological symptoms). Participants must be conscious, able to understand, and comply with study instructions. Clinical neurological examinations and imaging findings (MRI or CT) should demonstrate no new abnormalities.\n* Willingness to participate in and comply with rehabilitation programs.\n* Participants who have completed spinal cord electrical stimulation implantation surgery and\u002For are currently undergoing conventional rehabilitation therapy.\n\nExclusion Criteria:\n\n* Patients with untreated fractures of the upper extremities.\n* Patients with severe skin lesions or wounds that interfere with EMG electrode placement or the surgical sites for electrical stimulation implantation (e.g., chest\u002Fback, upper extremities, posterior cervical region, or subclavicular area).\n* Patients with a history of other neurological diseases.\n* Patients with known allergy or hypersensitivity to silver (Ag).",{"count":70,"type":21},20,"INTERVENTIONAL",[73],"NA","This study aimed to determine whether cervical spinal cord epidural electrical stimulation (EES) can activate upper-limb muscles in individuals with spinal cord injury.",[52],{"date":77,"type":32},"2026-07-24",{"date":79,"type":32},"2025-11-17",{"date":81,"type":21},"2027-12-31",{"name":38,"class":39},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":89,"targetDuration":4,"studyType":71,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":62},"100551057","epidural-electrical-stimulation-for-spinal-cord-injury-patients-and-corticospinal-motor-circuit-improvement-100551057","NCT06455137","Epidural Electrical Stimulation for Spinal Cord Injury Patients and Corticospinal Motor Circuit Improvement","Inclusion Criteria:\n\n* SCI ASIA: A, B, C,D\n* Between 20 and 70 year of age\n* \\>1 year post SCI\n* Complete or incomplete spinal cord injury.\n* Expected will undergo spinal cord stimulation surgery.\n* Continued rehabilitation after surgery for spinal cord injury.\n* Able to comply with procedures and follow up.\n* Stable medical condition without cardiopulmonary disease or dysautonomia that would - contraindicate participation in lower extremity rehabilitation or testing activities\n\nExclusion Criteria:\n\n* Have significant cognitive impairment (MMSE\\\u003C24).\n* Had a mental illness within one year or been treated in the past.\n* Have Major depressive disorder.\n* Active cancer diagnosis.\n* Painful musculoskeletal dysfunction, unhealed fracture, contracture, pressure sore, or urinary tract infection that might interfere with stand or step training.\n* Cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention.\n* Unable to read and\u002For comprehend the consent form.\n* Have concerns about this trial and do not sign consent.",{"count":70,"type":21},[73],"The study aims to examine the plausible interventional mechanisms underlying the effects of epidural spinal cord stimulation.",[93],"Spinal Cord Injuries","2026-07-21",{"date":96,"type":32},"2026-07-22",{"date":98,"type":32},"2024-04-30",{"date":36,"type":21},{"name":38,"class":39},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":62},"100647257","preoperative-anxiety-and-one-year-patient-reported-outcomes-in-orthopedic-surgery-patients-receiving-enhanced-recovery-after-surgery-or-conventional-care-100647257","NCT07706244","Preoperative Anxiety and One-year Patient-reported Outcomes in Orthopedic Surgery Patients Receiving Enhanced Recovery After Surgery or Conventional Care","A Prospective Cohort Study Comparing Preoperative Anxiety and One-Year Patient-Reported Outcomes Between Enhanced Recovery After Surgery and Conventional Care in Orthopedic Surgery Patients","ERAS-APO","Inclusion Criteria:\n\n* Inclusion Criteria:\n\n  1. Age \\>= 20 years.\n  2. Hospitalized patients scheduled for elective major orthopedic surgery (such as total knee arthroplasty, total hip arthroplasty, or spinal surgery).\n  3. Possess sufficient language comprehension and expression skills to complete interviews and questionnaires in Mandarin, Taiwanese, Hakka, or English.\n  4. Agree to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients requiring immediate management due to emergency or traumatic urgent surgery.\n2. Diagnosed by a physician with significant cognitive impairment, delirium, or severe mental illness resulting in the inability to complete evaluation and follow-up.\n3. Severe and unstable medical conditions (such as ASA-V, shock, or requiring long-term intensive care treatment).\n4. Anticipated requirement for intensive care unit (ICU) admission postoperatively.\n5. Concurrent participation in other clinical trials or intervention studies that would affect anxiety or functional outcomes.\n6. Patients for whom follow-up up to 12 months is inconvenient or difficult during the study period.","100 Years",{"count":111,"type":21},220,"This study investigates whether an Enhanced Recovery After Surgery (ERAS) program can help orthopedic surgery patients feel less anxious before their operation and recover better one year after surgery, compared to conventional (standard) surgical care.\n\nPatients who undergo orthopedic surgery, such as joint replacement, often experience significant anxiety before the operation. While ERAS programs, which combine patient education, pain management, and early mobilization, have been shown to shorten hospital stays and reduce complications, less is known about whether they also reduce preoperative anxiety and lead to better long-term outcomes reported by patients themselves.\n\nIn this prospective cohort study, patients receiving ERAS care will be compared with patients receiving conventional care. Preoperative anxiety will be measured using a validated questionnaire (APAIS). Clinical recovery during hospitalization, including length of stay, pain scores, and opioid use, will also be recorded. Patients will then be followed for one year to assess their quality of life (EQ-5D-5L) and their own impression of overall improvement (Patient Global Impression of Change).\n\nThe goal of this study is to determine whether ERAS not only improves short-term surgical recovery, but also reduces preoperative anxiety and leads to better long-term, patient-centered outcomes.",[114,115,116],"Preoperative Anxiety","Orthopedic Surgery","Patient Reported Outcome (PRO)",[118,119,120,121,122,123,124,125],"Enhanced Recovery After Surgery","ERAS","APAIS","EQ-5D-5L","Patient Global Impression of Change","Quality of Life","Cohort Study","Perioperative Care","2026-07-16",{"date":128,"type":32},"2026-07-17",{"date":130,"type":32},"2025-11-01",{"date":132,"type":21},"2027-12",{"name":38,"class":39},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":71,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":62},"100646773","effects-of-far-infrared-rays-and-transcutaneous-electrical-nerve-stimulation-on-short-term-prognosis-of-head-and-neck-cancer-patients-receiving-curative-treatment-100646773","NCT07689019","Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment","Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short-Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adults aged 30 to 85 years.\n2. Histologically confirmed head and neck cancer.\n3. Scheduled to concurrent chemoradiotherapy.\n4. Able to communicate verbally or in writing, willing to complete study questionnaires, and able to comply with all study procedures.\n\nExclusion Criteria:\n\n1. Presence of wounds or skin lesions at the sites where the transcutaneous electrical nerve stimulation electrodes will be applied.\n2. Contraindications to transcutaneous electrical nerve stimulation, including a history of epilepsy, brain tumor, arteriovenous malformation, implanted cardiac pacemaker, or implantable cardioverter-defibrillator, due to the potential risk of electrical stimulation interfering with the underlying medical condition.","30 Years","85 Years",{"count":144,"type":21},102,[73],"This clinical trial aims to evaluate whether far infrared radiation therapy and transcutaneous electrical nerve stimulation can reduce treatment-related side effects in patients with head and neck cancer undergoing concurrent chemoradiotherapy.\n\nThe primary objectives of this study are to determine whether far infrared radiation therapy and transcutaneous electrical nerve stimulation can improve shoulder pain and disability, cervical range of motion, maximum interincisal distance, oral mucositis, systemic inflammation, and chemotherapy-induced nausea and vomiting.\n\nParticipants will be randomly assigned to one of three groups: Group A will receive standard care (control group); Group B will receive standard care plus transcutaneous electrical nerve stimulation; and Group C will receive standard care plus far infrared radiation therapy combined with transcutaneous electrical nerve stimulation.\n\nThe intervention will be administered over two cycles of concurrent chemoradiotherapy, for a total of 10 intervention days. During each treatment cycle, participants in the intervention groups will receive the assigned treatment once every morning and once every evening for five consecutive days. Outcome assessments will be performed at three time points during each treatment cycle: before the intervention on Day 1 (baseline), after the intervention on Day 3, and after the intervention on Day 5.",[148],"Head and Neck Cancer (H&N)",[148,150,151],"transcutaneous electrical nerve stimulation","far infrared","2026-06-30",{"date":154,"type":32},"2026-07-07",{"date":156,"type":32},"2024-05-15",{"date":158,"type":21},"2026-12-31",{"name":38,"class":39},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":71,"phases":169,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":62},"100644029","social-prescribing-for-a-mindful-lifestyle-100644029","NCT07669805","Social Prescribing for a Mindful Lifestyle","Inclusion Criteria:\n\n* People aged 55 years or older.\n* People with a Geriatric Depression Scale (GDS-15) score of 7-10 or a UCLA Loneliness Scale Version 3 score of 35-64.\n* People can understand the research process, meet the requirements of the research, and can sign the informed consent and participate in the project.\n\nExclusion Criteria:\n\n* People that are unable to cooperate with the project or follow-up.\n* According to the PI's judgment, people with severe or poorly controlled conditions include ongoing acute diseases, severe infections, severe abnormal laboratory tests, or serious medical conditions with the following systems: cardiovascular, pulmonary, hepatic, nervous, mental, metabolic, renal, musculoskeletal, gastrointestinal, etc.\n* People with severe depression, risk of self-harm, severe cognitive impairment (dementia), visual or hearing impairment, and disabilities that prevent the completion of the project and assessment.\n* People are currently or expected to join any other physical training courses or nutrition intervention plans during the project period.\n* Others are based on the judgment of the PI that participating in this project may adversely affect the safety of the subjects, hinder the progress of the experiment, or interfere with the evaluation of the outcomes of the project.","55 Years",{"count":168,"type":21},50,[73],"The goal of this clinical trial is to evaluate the effectiveness of an 8-week mindfulness lifestyle social prescribing program in community-dwelling older adults aged 55 and older. The main questions it aims to answer are:\n\nTo establish a mindfulness lifestyle social prescribing model applied to the psychological and social health promotion of middle-aged and older populations.\n\nTo evaluate the effectiveness of the intervention on improving depressive symptoms, loneliness, and quality of life in this population.\n\nParticipants will receive an 8-week group intervention program, with each weekly session lasting approximately 3 hours. The structured curriculum integrates mindfulness awareness, body scanning, mindfulness stretching, breathing training, healthy dietary education, and art practices (such as herbal therapy and leaf printing). Researchers will collect and evaluate data from pre- and post-intervention assessments to measure changes in depressive symptoms, loneliness risk, and overall quality of life.",[172,173,174],"Depression and\u002For Anxiety in the Mild-to-moderate Range","Loneliness","Social Isolation",[176,177,178,123,179],"Mindfulness","Older Adults","Lifestyle Medicine","Social Prescribing","2026-06-21",{"date":182,"type":32},"2026-06-25",{"date":184,"type":21},"2026-07-01",{"date":186,"type":21},"2028-12-31",{"name":38,"class":39},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":195,"sex":16,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":71,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":62},"100638172","moxibustion-for-nocturia-100638172","NCT07598227","Moxibustion for Nocturia","Evaluation of the Efficacy and Safety of Acupoint Moxibustion for Nocturia: A Pilot Study","Inclusion Criteria:\n\n* Patients aged 40 years or older.\n* Experiencing two or more nocturia episodes per night.\n\nExclusion Criteria\n\n* Active urinary tract infection (UTI).\n* Poorly controlled diabetes mellitus (defined as HbA1c \\> 6.5%).\n* Presence of a neurogenic bladder caused by conditions such as multiple sclerosis, Parkinson's disease, stroke, spinal cord injury, or nerve damage resulting from major pelvic surgery.\n* Severe congestive heart failure (New York Heart Association \\[NYHA\\] functional class \\> II).\n* Use of other Traditional Chinese Medicine (TCM) therapies for nocturia symptoms within the past month (30 days).\n* Pregnant women.",true,"40 Years",{"count":20,"type":21},[73],"Nocturia, the interruption of sleep due to nighttime voiding, severely compromises quality of life, emotional health, and overall well-being when occurring twice or more per night. Given that some patients experience inadequate responses to conventional Western therapies or harbor concerns about the long-term side effects of pharmaceuticals, many are turning to Traditional Chinese Medicine (TCM) for alternative solutions. This study utilized a randomized clinical trial design to investigate the efficacy and safety of acupoint moxibustion for nocturia.",[201,202,203,204],"Nocturia","Acupoint","Moxibustion","Traditional Chinese Medicine","2026-05-17",{"date":207,"type":32},"2026-05-20",{"date":209,"type":32},"2025-01-01",{"date":158,"type":21},{"name":38,"class":39},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":218,"targetDuration":4,"studyType":71,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":229,"locationsCount":62},"100514706","epidural-electrical-stimulation-for-stroke-patients---improve-motor-and-sensory-function-and-alleviate-pain-100514706","NCT05981989","Epidural Electrical Stimulation for Stroke Patients - Improve Motor and Sensory Function and Alleviate Pain","Inclusion Criteria:\n\n* Between 20 and 70 years of age\n* First-ever clinical manifest stroke\n* Right or left hemiparesis\n* Scores higher than 7 and lower than 45 on the Fugl-Meyer scale.\n* Expected will undergo spinal cord stimulation surgery.\n* Able to comply with procedures and follow up.\n* Stable medical condition without cardiopulmonary disease or dysautonomia that would contraindicate participation in upper extremity rehabilitation or testing activities.\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding.\n* Have Major depressive disorder.\n* Had a mental illness within one year or been treated in the past.\n* Have significant cognitive impairment (MMSE\\\u003C24) or serious disease that could affect the ability to participate in study activities.\n* Cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention.\n* Receiving anticoagulant, anti-spasticity or anti-epileptic medications prior to or throughout the duration of the study.\n* Unable to read and\u002For comprehend the consent form.\n* Have concerns about this trial and do not sign consent.\n* Presence of joint contractures deemed by study clinician\u002Finvestigator to be too severe to participate in study activities.",{"count":70,"type":21},[73],"This study aims to verify whether epidural electrical stimulation (EES) of the cervical spinal cord can activate muscles of the upper limbs in people with hemiplegia following a stroke.",[222],"Stroke","2025-09-16",{"date":225,"type":32},"2025-09-19",{"date":227,"type":32},"2023-04-01",{"date":158,"type":21},{"name":38,"class":39},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":62},"100480881","the-use-of-molecular-radiogenomics-in-non-small-cell-lung-cancer-100480881","NCT05541744","The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer","NSCLC","Inclusion Criteria:\n\n* Age at least 20-years\n* Pathological proven non-small cell lung cancer and received complete staging work-up\n* Pre-treatment pathological specimen of the primary tumor\n\nExclusion Criteria:\n\n* Coexistence of non-aerodigestive tract cancer.\n* Unable to comply to FDG PET\u002FCT exam or poor image quality\n* Unable to determine the primary tumor",{"count":238,"type":21},120,"Lung cancer is currently the leading cause of cancer-related mortality worldwide, and the dominant histopathology is non-small cell lung cancer (NSCLC). Although many new targeted and immunomodulation therapies have emerged, not all patients are responsive to novel therapeutics. A more reliable and accurate risk stratification model to predict the treatment response and survival outcomes are still lacking. The 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) derived radiomics can be used to interrogate tumor biologies such as glycolytic activity and heterogeneity. It can, therefore, be used to predict treatment response and survival outcomes. Cancer genomics derived from gene sequencing can evaluate cancer's genetic alterations. It can be used to feature the genotype of the tumor. However, both tools have drawbacks; combining these two modalities may enable a more robust predictive model for more precise clinical decisions. During the investigator's former study project, the investigators published four Science Citation Index journal papers using the investigators' research results, which found that 18F-FDG PET radiomics can independently predict regional lymph node metastasis in NSCLC and cancer survival by stage. The preliminary findings of the investigator's former research project also disclosed an association between 18F-FDG PET-derived molecular radiomics with genomic heterogeneity and mutation of specific glucose metabolic genes. This time, the investigators plan to include deep radiomics in addition to traditional handcrafted radiomics. The investigators aim to investigate the radiogenomic patterns in different driver gene mutation statuses and clinical scenarios. Finally, the investigators seek to use radiogenomics as a prognostic stratification tool in patients with NSCLC.",[241],"Lung Cancer",[243,244,245,246,247],"non-small cell lung cancer","Radiogenomics","18F-FDG PET","whole exome sequencing","molecular imaging","2025-09-15",{"date":225,"type":32},{"date":251,"type":32},"2023-08-01",{"date":253,"type":21},"2028-07-31",{"name":38,"class":39},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":71,"phases":262,"briefSummary":263,"conditions":264,"keywords":267,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":280,"locationsCount":4},"100597557","the-effects-of-a-dialysis-specific-formula-rich-in-branched-chain-amino-acids-omega-3-and-dietary-fiber-on-nutritional-status-100597557","NCT07060040","The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status","Inclusion Criteria:\n\n* Patients with ESRD who have been receiving dialysis for more than three months\n* Serum albumin (Alb) ≤ 4.0 g\u002FdL, or body mass index (BMI) ≤ 20, or normalized protein catabolic rate (nPCR) ≤ 0.8\n* Male or female patients aged 20 years or older\n\nExclusion Criteria:\n\n* Serum albumin (Alb) \\\u003C 3.0 g\u002FdL\n* Known allergy or intolerance to any component of the product, or deemed by a physician to be unable to complete the trial\n* Patients who refuse to sign the informed consent form or are unable to follow study instructions\n* Pregnant or breastfeeding women\n* Patients with severe illnesses (including burn injuries), undergoing major surgery, with abnormal liver function (GOT and GPT levels more than 5 times the upper limit of normal), or with malignancy (6) Participation in another clinical trial of investigational drugs or concurrent use of investigational drugs within 30 days prior to or during this trial (7) Any other serious medical condition as determined by the investigator that would make the patient unsuitable for participation",{"count":20,"type":21},[73],"The aim of this study is to evaluate the effects of a specialized oral nutritional supplement (SF) enriched with BCAAs, omega-3 fatty acids, and dietary fiber on improving the nutritional status of dialysis patients with mild to moderate malnutrition, and thereby alleviating fatigue and enhancing quality of life. We will assess various aspects of protein-energy wasting (PEW), as well as changes in the Malnutrition Inflammation Score (MIS), Geriatric Nutritional Risk Index (GNRI), fatigue, appetite, serum BCAA levels, uremic toxins, and gut microbiota composition.",[265,266],"ESRD (End-Stage Renal Disease)","Dialysis",[268,269,270,271,272,273],"Branched-chain amino acid","Protein-energy malnutrition","fiber","omega-3","oral nutritional supplements","dialysis","2025-07-01",{"date":276,"type":32},"2025-07-11",{"date":278,"type":21},"2025-07",{"date":132,"type":21},{"name":38,"class":39},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":195,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":71,"phases":290,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":4},"100578994","huandao-conditioning-application-for-allergic-rhinitis-treatment-100578994","NCT06818526","Huandao Conditioning Application for Allergic Rhinitis Treatment","A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Evaluate the Efficacy and Safety of Huandao Conditioning Application in Adults with Allergic Rhinitis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* RCAT score \\\u003C 21\n* Positive allergen screening (\\> 0.35 KU\u002FL for house dust, microbial, or pet dander)\n* Capable of operating mobile app and completing follow-up\n\nExclusion Criteria:\n\n* Recent diagnosis, active treatment, or recurrence risk of head\u002Fneck cancer\n* Current or previous immunotherapy\n* Any condition that may compromise participant safety or interfere with trial assessment per investigator judgment",{"count":289,"type":21},95,[73],"The goal of this clinical trial is to learn if the Huandao Conditioning Application works to treat allergic rhinitis in adults. It will also learn about the safety of this application. The main questions it aims to answer are:\n\nDoes the Huandao Conditioning Application improve allergic rhinitis symptoms as measured by the Rhinitis Control Assessment Test (RCAT) and nasal airway resistance tests? What medical problems do participants have when using the Huandao Conditioning Application?\n\nResearchers will compare the therapeutic version of the application to a placebo version (a look-alike application that contains no therapeutic effect) to see if the Huandao Conditioning Application works to treat allergic rhinitis.\n\nParticipants will:\n\nUse either the therapeutic or placebo version of the application daily for 1 week in Phase 1 Take a 2-week break with no application use Use the opposite version of the application daily for 1 week in Phase 2 Visit the clinic at the beginning and end of each phase for checkups and tests Complete symptom assessment questionnaires before each application use and 1-2 hours after use Be monitored for any adverse reactions throughout the study period",[293],"Allergic Rhinitis",[295],"allergic rhinitis","2025-02-11",{"date":298,"type":32},"2025-02-13",{"date":300,"type":21},"2025-03-01",{"date":158,"type":21},{"name":38,"class":39},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":309,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":71,"phases":311,"briefSummary":312,"conditions":313,"keywords":317,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":62},"100494701","effectiveness-of-integrated-care-combined-nutrition-and-lifestyle-counselling-in-frail-older-patients-with-diabetes-100494701","NCT05721599","Effectiveness of Integrated Care Combined Nutrition and Lifestyle Counselling in Frail Older Patients With Diabetes","Inclusion Criteria:\n\n* People aged 65 years or older.\n* People with Clinical Frailty Scale: 4-7.\n* People with a history of type II diabetes, use of diabetes medications, or HbA1c greater than or equal to 6.5%.\n* People can understand the research process, meet the requirements of the research, and can sign the informed consent and participate in the following tracking.\n\nExclusion Criteria:\n\n* People that are unable to cooperate with or accept intervention or follow-up.\n* People with a history of type I diabetes.\n* People use insulin injections or pumps.\n* According to the PI's judgment, people with severe or poorly controlled conditions include acute diseases, severe infections, severe abnormal laboratory tests, or serious medical conditions with the following systems: cardiovascular, pulmonary, hepatic, nervous, mental, metabolic, renal, musculoskeletal, gastrointestinal, etc.\n* People with severe visual or hearing impairment that prevent the completion of assessment and testing.\n* People with malignant tumors that have just been diagnosed or are undergoing treatment or are still at risk of recurrence.\n* People have received hormone therapy within three months before the trial or are expected to receive hormone therapy during the trial.\n* People are currently or expected to join any other physical training courses or nutrition plans during the trial.\n* Others are based on the judgment of the PI that participating in this trial may adversely affect the safety of the subjects, hinder the progress of the experiment, or interfere with the evaluation of the outcomes of the trial.","65 Years",{"count":20,"type":21},[73],"The goal of this clinical trial is to evaluate the effectiveness of innovative integrated care in pre-frail or frail patients with diabetes over 65 years old. The main questions it aims to answer are:\n\n* To establish innovative integrated care for frail elderly patients with diabetes combined with nutrition and lifestyle guidance.\n* To evaluate the effectiveness of the intervention compared with general outpatient care.\n\nParticipants will receive 12 weeks of structured care including specialist care, integrated assessment, group health education, one-on-one nutrition and lifestyle guidance, online and face-to-face support group, and case management. Researchers will compare general outpatient care to see its effects on frailty, physical function, and blood sugar control.",[314,315,316],"Frailty","Diabetes","Lifestyle",[314,315,318,319,320,316],"Older adult","Integrated care","Nutrition","2024-08-05",{"date":323,"type":32},"2024-08-07",{"date":325,"type":32},"2023-04-13",{"date":327,"type":21},"2025-12-31",{"name":38,"class":39},""]